BRANFORD, Conn. / Nov 05, 2024 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it will be participating in two upcoming investment conferences.
Jeff Hawkins, Quantum-Si's Chief Executive Officer, will participate in a fireside chat discussion at the UBS Global Healthcare Conference on Wednesday, November 13th, at 8:45 AM PT.
On Thursday, November 21st at 8:00 AM ET, Mr. Hawkins will participate in a fireside chat discussion at the Canaccord Medtech, Diagnostics & Services Forum in New York City.
A live and archived webcast of the event will be available in the “Investors” section of the Quantum-Si website under Events & Presentations.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® instrument enables Next-Generation Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.
| Last Trade: | US$1.99 |
| Daily Change: | 0.09 4.74 |
| Daily Volume: | 5,606,179 |
| Market Cap: | US$275.420M |
June 17, 2025 June 10, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
